Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Genoa Ventures

Investor type Venture Capital
Founders Jenny Rooke


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 30
Average round size
The average size of a deal this fund participated in
Portfolio companies 22
Rounds per year 3.75
Lead investments 6
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 3
Key employees 1
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Life Science
  • Medical
  • Health Diagnostics

In 2014 was created Genoa Ventures, which is appeared as VC. The venture was found in North America in United States. The main office of represented VC is situated in the San Francisco.

The fund was created by Jenny Rooke.

The top activity for fund was in 2017. Considering the real fund results, this VC is 11 percentage points more often commits exit comparing to other organizations. Opposing the other organizations, this Genoa Ventures works on 21 percentage points less the average amount of lead investments. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 investment rounds annually.

Among the most popular portfolio startups of the fund, we may highlight Zymergen, Caribou Biosciences, Akadeum Life Sciences. Among the most popular fund investment industries, there are Pharmaceutical, Biopharma. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Genoa Ventures, startups are often financed by Cultivation Capital, Serra Ventures, Novartis. The meaningful sponsors for the fund in investment in the same round are Jenny Rooke, True Ventures, Shu Duan. In the next rounds fund is usually obtained by Threshold, Innovation Endeavors, Data Collective DCVC.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Genoa Ventures:
Typical Co-investors
Genoa Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Genoa Ventures:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Alpha Intelligence Capital Luxembourg, Luxembourg
Asia United Fund -
Gati Kausar Andhra Pradesh, India, Secunderabad
ProSiebenSat.1 Media SE Bayern, Germany, Unterföhring
Research Corporation Technologies Arizona, Tucson, United States
Ruisi Guquan Touzi China, Ningbo, Zhejiang
Shanghai Liuhe Capital China, Shanghai
Tangtaike Touzi China, Jiangsu, Nanjing
Targeted Technology Fund San Antonio, Texas, United States
Toa Capital Corporation Japan, Tokyo

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


Environmental Consulting
Health Care
Renewable Energy
$33M15 Sep 2022 Cambridge, Massachusetts, United States

Bond Pet Foods

Health Care
$17M07 Sep 2022 Boulder, Colorado, United States

Codetta Biosciences

Clinical Trials
Product Research
$15M07 Apr 2022 Morrisville, North Carolina, United States


Emergency Medicine
Health Care
Health Diagnostics
Home Health Care
Medical Device
$12M16 Feb 2022 Salt Lake City, Utah, United States


Life Science
$12M14 Dec 2021 Paris, Ile-de-France, France


Life Science
$15M26 Oct 2021 Champaign, Illinois, United States


Life Science
$201M02 Aug 2021 South San Francisco, California, United States

Stemson Therapeutics

$15M15 Jul 2021 San Diego, California, United States


Health Care
$4M01 Jul 2021 Orinda, California, United States
SimBioSys Raises $15 Million Series A to Develop the Future of Precision Cancer Care

– SimBioSys announced it raised $15m in Series A funding to accelerate the development and commercialization of its TumorScope software platform.
– The company’s novel, simulation-based, precision medicine platform enables individualized treatment planning for cancer patients.
– This Series A was co-led by Genoa Ventures and Northpond Ventures, with participation from AV8 Ventures, Heritage Medical Group, and Mayo Clinic.
– Existing investors and founders also participated in this financing round, bringing the company’s total capital raised to $21m.
– In the first half of 2021, SimBioSys tripled its headcount, bringing in expert clinicians, scientists, and executives from the life sciences industry.

InterVenn Biosciences Raises $201 Million for AI-driven Glycoproteomic Platform, Liquid-Biopsy development

– InterVenn Biosciences announced the completion of a $201m Series C financing.
– The funding round was led by new investors SoftBank Group, Heritage Provider Network, Irving Investors, Highside Capital Management, and backed by existing investors Amplify Partners, Anzu Partners, Genoa Ventures and True Ventures.
– The proceeds from the financing will be used to accelerate development and commercialization of Dawn, the company’s liquid biopsy assay for immune checkpoint inhibitor response prediction, and to expand the network of partners on the company’s AI-driven glycoproteomics platform.
– To date, the InterVenn glycoproteomics platform has been used to develop 16 clinical use cases across oncology and other indications. Dawn is currently under development and is planned to be commercialized in 2022.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Genoa Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: